semaglutide heart failure ameliorates pressure overload-induced cardiac hypertrophy by improving cardiac mitophagy to suppress the activation of NLRP3 inflammasome Weight loss injections can reduce

In a substantial 72-week study involving 751 participants with obesity or overweight, Tirzepatide achieved an average weight loss of 20.2%, equating to approximately 50.3 pounds (22.8 kg)

For others, it softened trauma symptoms, helped with sleep, created confidence in social settings, or made unbearable feelings feel distant for a while

Emphasizing preventive measures related to foot and eye care is crucial for patients with diabetes to minimize the risk of complications that could significantly impact their quality of life

On 20 March 2026, semaglutide's Indian patent expired

Below are common qualifying conditions and how each one affects eligibility